摘要
目的 探讨托珠单抗治疗儿童多发性大动脉炎(TA)的疗效及其对炎症因子水平的影响.方法 选取2021年1月至2022年12月山东大学附属儿童医院肾脏风湿免疫科收治60例TA患儿作为研究对象,按照抽签法随机分为常规治疗组(30例)及托珠单抗组(30例),常规治疗组采用激素联合环磷酰胺治疗,托珠单抗组在常规治疗组基础上采用托珠单抗治疗.比较两组治疗前后血白细胞(WBC)、C反应蛋白(CRP)、红细胞沉降率(ESR)、血清白细胞介素(IL)-6、IL-2R、IL-8及肿瘤坏死因子α(TNF-α)水平.结果 两组患儿治疗前均有发热,托珠单抗组的体温恢复正常时间短于常规治疗组,差异有统计学意义(P＜0.05).治疗后托珠单抗组的WBC、ESR、CRP、IL-6、IL-2R、TNF-α、IL-8水平低于常规治疗组,差异有统计学意义(P＜0.05).结论 TA患儿应用托珠单抗治疗后,炎症指标及细胞因子水平均较前明显下降,有助于监测TA病情活动及药物疗效.
Abstract
Objective To explore the efficacy of Tozumab in the treatment of children with Takayasu arteritis(TA)and its impact on the levels of inflammatory factors.Methods Sixty children with TA admitted to the Department of Renal Rheuma-tology and Immunology,Children's Hospital Affiliated to Shandong University from January 2021 to December 2022 were selected as the study subjects.They were divided into a conventional treatment group(30 cases)and a Tozumab group(30 cases)according to the lottery method.The conventional treatment group received hormone combined with CTX treatment,while the Tozumab group received treatment with Tozumab on the basis of the conventional treatment group.The levels of white blood cell(WBC),C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),serum interleukin(IL)-6,IL-2R,IL-8,and tumor necrosis factor α(TNF-α)between the two groups before and after treatment were compared.Results Both groups of children had fever before treatment,and the temperature recovery time in the Tozumab group was shorter than that in the conventional treatment group,with statistically significant difference(P＜0.05).After treatment,the levels of WBC,ESR,CRP,IL-6,IL-2R,TNF-α and IL-8 in Tozumab group were lower than those in conventional treatment group,and the differences were statistically significant(P＜0.05).Conclusion After treatment with Tozumab,the inflamma-tory indicators and cytokine levels in children with TA decreased significantly compared to before,which helps to monitor TA's disease activity and drug efficacy.
基金项目
山东省济南市卫生健康委科技计划项目(2022-2-151)
山东省济南市卫生健康委员会院内大数据科技计划项目(2022-YBD-14)
维普
万方数据